HomeCompareNRBO vs ORCC

NRBO vs ORCC: Dividend Comparison 2026

NRBO yields 84.75% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NRBO wins by $2.02M in total portfolio value
10 years
NRBO
NRBO
● Live price
84.75%
Share price
$2.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.05M
Annual income
$615,863.14
Full NRBO calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — NRBO vs ORCC

📍 NRBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNRBOORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NRBO + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NRBO pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NRBO
Annual income on $10K today (after 15% tax)
$7,203.39/yr
After 10yr DRIP, annual income (after tax)
$523,483.67/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, NRBO beats the other by $523,482.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NRBO + ORCC for your $10,000?

NRBO: 50%ORCC: 50%
100% ORCC50/50100% NRBO
Portfolio after 10yr
$1.03M
Annual income
$307,932.09/yr
Blended yield
29.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

NRBO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-20.1
Piotroski
0/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NRBO buys
0
ORCC buys
0
No recent congressional trades found for NRBO or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNRBOORCC
Forward yield84.75%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$2.05M$21.4K
Annual income after 10y$615,863.14$1.04
Total dividends collected$1.79M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: NRBO vs ORCC ($10,000, DRIP)

YearNRBO PortfolioNRBO Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$19,175$8,474.58$11,190$489.61+$8.0KNRBO
2$35,703$15,186.58$12,229$256.01+$23.5KNRBO
3$64,630$26,427.72$13,216$130.74+$51.4KNRBO
4$113,864$44,709.84$14,207$66.02+$99.7KNRBO
5$195,450$73,615.70$15,234$33.17+$180.2KNRBO
6$327,228$118,096.19$16,317$16.62+$310.9KNRBO
7$534,919$184,784.73$17,468$8.32+$517.5KNRBO
8$854,669$282,305.61$18,695$4.16+$836.0KNRBO
9$1,336,042$421,546.65$20,006$2.08+$1.32MNRBO
10$2,045,428$615,863.14$21,407$1.04+$2.02MNRBO

NRBO vs ORCC: Complete Analysis 2026

NRBOStock

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Full NRBO Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this NRBO vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NRBO vs SCHDNRBO vs JEPINRBO vs ONRBO vs KONRBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.